CN114364377A - 可用于治疗具有kras或hras突变或扩增的癌症的方法 - Google Patents

可用于治疗具有kras或hras突变或扩增的癌症的方法 Download PDF

Info

Publication number
CN114364377A
CN114364377A CN202080063214.7A CN202080063214A CN114364377A CN 114364377 A CN114364377 A CN 114364377A CN 202080063214 A CN202080063214 A CN 202080063214A CN 114364377 A CN114364377 A CN 114364377A
Authority
CN
China
Prior art keywords
cancer
compound
subject
administering
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080063214.7A
Other languages
English (en)
Chinese (zh)
Inventor
D·海勒
C·霍罗斯科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of CN114364377A publication Critical patent/CN114364377A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080063214.7A 2019-07-15 2020-07-15 可用于治疗具有kras或hras突变或扩增的癌症的方法 Pending CN114364377A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962874474P 2019-07-15 2019-07-15
US62/874,474 2019-07-15
PCT/US2020/042162 WO2021011674A1 (en) 2019-07-15 2020-07-15 Methods useful in treating cancers harboring a kras or hras mutation or amplification

Publications (1)

Publication Number Publication Date
CN114364377A true CN114364377A (zh) 2022-04-15

Family

ID=74211326

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080063214.7A Pending CN114364377A (zh) 2019-07-15 2020-07-15 可用于治疗具有kras或hras突变或扩增的癌症的方法

Country Status (7)

Country Link
US (1) US20220257599A1 (https=)
EP (1) EP3999049A4 (https=)
JP (1) JP2022540921A (https=)
CN (1) CN114364377A (https=)
AU (1) AU2020315388A1 (https=)
CA (1) CA3147588A1 (https=)
WO (1) WO2021011674A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102679204B1 (ko) * 2021-02-10 2024-06-27 한국생명공학연구원 GPX4 저해제 및 Lp-PLA2 저해제를 포함하는 암 예방 또는 치료용 조성물
WO2024077085A1 (en) * 2022-10-07 2024-04-11 Memorial Sloan-Kettering Cancer Center Targeting phospholipase a2 (pla2) in cancer
US12314787B2 (en) 2023-04-27 2025-05-27 Hewlett Packard Enterprise Development Lp Serving application programming interface calls directed to hierarchical data format files stored in fabric-attached memories

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102166364A (zh) * 2011-04-14 2011-08-31 江南大学 用于治疗卵巢癌的钙离子非依赖性磷脂酶a2的抑制剂
US20190142835A1 (en) * 2017-11-14 2019-05-16 Oregon Health & Science University Inhibition of autophagy using phospholipase a2 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150017671A1 (en) * 2004-04-16 2015-01-15 Yaping Shou Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
CA2830958A1 (en) * 2011-04-06 2012-10-11 The Scripps Research Institute N1- and n2-carbamoyl-1,2,3-triazole serine hydrolase inhibitors and methods
KR20160117596A (ko) * 2014-02-07 2016-10-10 오스펙스 파마슈티칼스, 인코포레이티드 신규 제약 제제
AU2017329090B9 (en) * 2016-09-19 2019-09-05 Novartis Ag Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102166364A (zh) * 2011-04-14 2011-08-31 江南大学 用于治疗卵巢癌的钙离子非依赖性磷脂酶a2的抑制剂
US20190142835A1 (en) * 2017-11-14 2019-05-16 Oregon Health & Science University Inhibition of autophagy using phospholipase a2 inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
RUI MAO等: "A multiplex microfluidic loop-mediated isothermal amplification array for detection of malaria-related parasites and vectors", ACTA TROPICA, vol. 178, pages 124 *
杜丽芬;杨慧龄;: "Caveolin-1在肿瘤发生发展及耐药机制中的作用", 国际病理科学与临床杂志, vol. 27, no. 04, pages 314 - 318 *

Also Published As

Publication number Publication date
WO2021011674A1 (en) 2021-01-21
EP3999049A1 (en) 2022-05-25
AU2020315388A1 (en) 2022-02-17
JP2022540921A (ja) 2022-09-20
EP3999049A4 (en) 2023-07-26
CA3147588A1 (en) 2021-01-21
US20220257599A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
Zhang et al. Adipocyte-derived lipids mediate melanoma progression via FATP proteins
Hasako et al. TAS6417, a novel EGFR inhibitor targeting exon 20 insertion mutations
Rysman et al. De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturation
McHugh et al. COPI vesicle formation and N-myristoylation are targetable vulnerabilities of senescent cells
Cheng et al. Dual inhibition of CDK12/CDK13 targets both tumor and immune cells in ovarian cancer
Francis et al. H3 histamine receptor–mediated activation of protein kinase Cα Inhibits the growth of cholangiocarcinoma in vitro and in vivo
CN114364377A (zh) 可用于治疗具有kras或hras突变或扩增的癌症的方法
CN116234547A (zh) N-豆蔻酰基转移酶(nmt)抑制剂在治疗癌症、自身免疫性病症和炎症性病症中的用途
US10898473B2 (en) Combinations to treat cancer
Dimri et al. Noncanonical pS727 post translational modification dictates major STAT3 activation and downstream functions in breast cancer
KR102824773B1 (ko) 대사성 질환 및/또는 그것의 임상적 상태를 억제 및/또는 치료하기 위한 조성물 및 방법
Qin et al. CCT251545 enhances drug delivery and potentiates chemotherapy in multidrug-resistant cancers by Rac1-mediated macropinocytosis
KR101892908B1 (ko) 글루코코르티코이드계 화합물을 포함하는 비소세포성 폐암 치료용 약학 조성물
WO2016076359A1 (ja) イベルメクチン又はミルベマイシンｄを有効成分として含む抗癌剤
US20230151434A1 (en) Reawakening of dormant tumor cells by modified lipids derived from stress activated neutrophils
TW201628624A (zh) 使用啡噻嗪用於治療癌症的醫藥組成物
US20220288130A1 (en) Compositions and methods for diagnosis and treatment of metabolic diseases and disorders
US20200101070A1 (en) Methods of treating cancer having an active wnt/beta-catenin pathway
Bandi et al. ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma
US20240000977A1 (en) Methods and kits for diagnosing and treating cancers
EP4541366A1 (en) Pharmaceutical composition comprising foxm1 inhibitor and immune checkpoint inhibitor for preventing or treating cancer
Poku Identification and Characterization of Modulators of Human MRP1 (ABCC1) and Human MRP2 (ABCC2) Expression
Fontana Linking metabolic reprogramming to chemo-immuno-resistance: identifying new predictive biomarkers and druggable targets moving from OMIC techniques to single cell analysis
Anania Identification of myoferlin as a component of mitochondria-associated membranes and discovery of a new function in calcium transfer in PDAC cell lines
Riyahi Therapeutic Targeting of BET Proteins in Osteosarcoma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220415

WD01 Invention patent application deemed withdrawn after publication